Tango Therapeutics reported raising $15 Million in an initial SEC Form D filing, from an offering of $15 Million
PUBLIC · TNGXOct 28, 2025
Amount Raised
$15 Million
$15 Million sold, per SEC Form D (first sale Oct 24, 2025)
Round Type
Venture
BostonHealthcareHealth Care
Quick answer
Tango Therapeutics raised $15 Million in a funding round, dated October 24, 2025. Tango Therapeutics is based in Boston, Massachusetts, United States.
How much did Tango Therapeutics raise?
Tango Therapeutics raised $15 Million in a funding round on October 24, 2025.
What does Tango Therapeutics do?
Tango Therapeutics is a clinical-stage biotechnology company pioneering the next generation of precision cancer medicines.
Where is Tango Therapeutics based and how big is it?
Tango Therapeutics is based in Boston, Massachusetts, United States. Fundz records about 169 employees.
Who are the decision-makers at Tango Therapeutics?
Fundz holds 3 contacts at Tango Therapeutics, including the Senior Information Technology Manager. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who to call at Tango Therapeutics, and when
A new round usually means Tango Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Tango Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Tango Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Tango Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Tango Therapeutics
Location
201 BROOKLINE AVENUE
Boston, Massachusetts, United States
About
Tango Therapeutics is a clinical-stage biotechnology company pioneering the next generation of precision cancer medicines. Founded in 2017 with a $55 million Series A investment from Third Rock Ventures, the company leverages advances in DNA sequencing and CRISPR-based target discovery to develop breakthrough therapies with deeper, more durable benefits than current treatments. Focused on three key areas—loss of tumor suppressor gene function, multiple oncogenic drivers, and immune evasion—Tango uses synthetic lethality to selectively target cancer cells while sparing healthy tissue. By combining deep genetic insights with cutting-edge science, Tango aims to accelerate the development of transformational therapies for patients with cancers lacking effective treatment options.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Tango Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.